Skip to content

Study · In vitro (cells) · 2006

2 results

The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas.

Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, Swearingen B, Hedley-Whyte ET, Stratakis CA, Klibanski A

The Journal of clinical endocrinology and metabolism29 Aug 2006Cited by 141 (Europe PMC)

PMID16940446 (opens in a new tab)DOI10.1210/jc.2006-1245 (opens in a new tab)PepBankPUB-16940446
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In human corticotroph adenoma cultures, pasireotide significantly suppressed proliferation by 10-70% across all six tumors.

    In plain wordsIn cells from human corticotroph adenomas, pasireotide reduced proliferation by 10-70%.

    Peptide
    Pasireotide
    Outcome
    DecreaseCell proliferation
    Study

    humann = 6

    Primary human corticotroph adenoma cultures
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Measurements

    Proliferation suppression range
    10 to 70%
    all six cultured tumors
    P value range
    0.045 to 0.001
    cell proliferation suppression

    Source sentences

    Summary
    Significant suppression of cell proliferation was observed in all tumors cultured (percent suppression range: 10-70%; P = 0.045-0.001).
    1 context sentence
    Summary · context
    SOM230 effects on cell proliferation and ACTH release were evaluated in vitro using primary cultures of six of the 13 human corticotroph adenomas.
  2. 02LabIn vitro (cells)Activity measurement

    In human corticotroph adenoma cultures, pasireotide significantly inhibited ACTH secretion in five of six tumors, with suppression of 23-56%.

    In plain wordsIn cells from human corticotroph adenomas, pasireotide reduced ACTH secretion in five of six tumors.

    Peptide
    Pasireotide
    Outcome
    DecreaseACTH secretion
    Study

    humann = 6

    Primary human corticotroph adenoma cultures
    Outcome group
    Endogenous peptide levels · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    ACTH suppression range
    23 to 56%
    five of six cultured tumors
    P value range
    0.042 to 0.001
    ACTH secretion suppression

    Source sentences

    Summary
    SOM230 inhibited ACTH secretion in five of the six tumors cultured (percent suppression range: 23-56%; P = 0.042-0.001).
    1 context sentence
    Summary · context
    SOM230 effects on cell proliferation and ACTH release were evaluated in vitro using primary cultures of six of the 13 human corticotroph adenomas.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.